Slide 1: Investor Presentation July 2026
Investor Presentation July 2026
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Senores Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for a
Slide 3: Financial & Operational Highlights Q1 FY27
Financial & Operational Highlights Q1 FY27 Private & Confidential
Slide 4: Key Highlights Q1FY27
Key Highlights Q1FY27 • Consistently delivering robust performance with Revenues for Q1FY27 growing by 36% Y-o-Y • Strong revenue growth delivered in Regulated & Emerging markets with revenue growth of 42% & 30% respectively on a Y-o-Y basis • EBIDTA for Q1FY27 grew by 87% with margin expansion of ~
Slide 5: Regulated Market Owned Product Portfolio & Visibility
Regulated Market Owned Product Portfolio & Visibility Owned ANDAs Corresponding ANDA Products* Huge Opportunity Q1FY26 Q1FY27 Q1FY26 Q1FY27 Approved ANDAs 30 58 70 187 Scaled up Own ANDAs by 2x and Corresponding ANDA products by nearly 2.5x over the past 12 months Commercialized ANDAs 12 23 24 51 35
Slide 6: CDMO / CMO & Emerging Market Opportunity
CDMO / CMO & Emerging Market Opportunity Products Corresponding ANDA Products* Huge Opportunity Q1FY26 Q1FY27 Q1FY26 Q1FY27 CDMO/CMO business focused on specialty, government supplies CDMO/ CMO and controlled substances. Commercialized Products 15 16 27 34 Uniquely positioned in USA & India to provi
Slide 7: Consolidated Financial Highlights – Q1 FY27
Consolidated Financial Highlights – Q1 FY27 Revenue (₹ Crs) EBITDA (₹ Crs) PAT (₹ Crs) 36% 87% 56% 180.2 53.8 30.7 132.6 19.7 28.8 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Gross Margin (%) EBITDA Margin (% ) PAT Margin (%) +980 bps +810 bps +220 bps 63.5% 29.8% 17.0% 53.7% 14.9% 21.7% Q1 FY26
Slide 8: Segmental Financial Highlights – Q1 FY27
Segmental Financial Highlights – Q1 FY27 Segment Revenue (₹ Crs) Q1FY27 Q1FY26 Y-o-Y FY26 FY25 Y-o-Y Regulated Markets 127.8 90.1 41.9% 427.4 244.8 74.6% Emerging Markets 37.6 29.0 29.6% 145.0 121.2 19.7% Branded Generics 8.0 8.2 -2.4% 40.0 8.2 385.3% Others (Incl. API Sales) 6.8 5.2 29.2% 20.3 36.2
Slide 9: Consolidated Profit & Loss Account – Q1 FY27
Consolidated Profit & Loss Account – Q1 FY27 Consolidated P&L (₹ Crs) Q1 FY27 Q1 FY26 Y-o-Y FY26 FY25 Y-o-Y Revenue from Operations 180.2 132.6 35.9% 632.6 410.3 54.2% Cost of Goods Sold 65.7 61.4 251.7 180.7 Gross Profit 114.5 71.3 60.6% 381.0 229.6 65.9% Gross Margin (%) 63.5% 53.7% 980 bps 60.2%
Slide 10: Update on Utilization of Funds from IPO
Update on Utilization of Funds from IPO Amount as proposed in the Amount utilized till June 2026 Amount unutilized as on 30th No. Object as per Offer Document Offer Document and as (₹ Crs) June 2026 (₹ Crs) Revised (₹ Crs) Investment in one of our Subsidiaries, Havix, to fund capital expenditure 1 r
Slide 11: Growth Strategies
Growth Strategies Private & Confidential
Slide 12: Growth Strategies
Growth Strategies Significantly enhance market Inorganic growth through synergistic acquisitions presence in North America & other Regulated Markets Integrated approach by Launch products with the potential enhancing capabilities for of NDA approval in the US backward integration Expanding into new
Slide 13: About Senores Pharmaceuticals Limited
About Senores Pharmaceuticals Limited Private & Confidential
Slide 14: Introduction to Senores Pharmaceuticals
Introduction to Senores Pharmaceuticals Brief Overview Global Research driven Formulation Focused company engaged in developing & At a Glance manufacturing of pharmaceutical products predominantly for the Regulated Markets of the US, Canada, UK and others across various therapeutic areas Niche Produ
Slide 15: Corporate Structure
Corporate Structure Senores Pharmaceuticals Inc. US based company holding ANDAs 100% Marketing cum ANDA and mutually exclusive marketing Subsidiary Holding Company relationships with customers Engaged in the Contract Senores Pharmaceuticals Inc. Development & Manufacturing of 73.28% 1 Marketing cum
Slide 16: Four Business Segments
Four Business Segments 71% 21% 4% 4% FY26 Revenue Regulated Markets Emerging Markets Branded Generics Others ₹ 180 Crs Regulated Markets Business Emerging & Mid-Tier Markets Business Develop & manufacture pharmaceutical products for the Primarily serves the US, Canada and United Kingdom Emerging & M
Slide 17: Distinct Specialty & Complex Product Portfolio Built in a Short Span
1 Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets Demonstrated Capability to Propel Products from Conception to Commercialization Product Identification Product Development Commercial Data Analysis – IQVIA, R&D to establish API Partner Finalization Concurre
Slide 18: Key Strengths of the Company
Key Strengths of the Company Distinct Specialty and Complex Product Portfolio built in a short span for Regulated Markets Direct access to the US Government supplies through its subsidiary Enabling Forward Integration via our subsidiary, catering directly to B2C and Veterinary market Strong R&D capa
Slide 19: Key Events & Milestones
Key Events & Milestones Acquired a 51% stake in Zoraya Incorporated a wholly owned Consolidated presence in emerging Pharmaceuticals, LLC (Nov 2025) Incorporated as “Senores subsidiary, Senores Pharmaceuticals markets by acquiring shares in Ratnatris Acquired 75% stake in Apnar Pharmaceuticals Pvt.
Slide 20: Presence in Regulated Markets through Long-term marketing arrangements
2 Presence in Regulated Markets through Long -term marketing arrangements MARKETED PRODUCTS CDMO / CMO Business Model Business Model Identify, Develop & Commercialize specialty & complex Customized formulation, development & manufacturing niche products in mid - market range capabilities for custome
Slide 21: Presence in the Emerging & Mid-Tier Markets with Portfolio
3 Presence in the Emerging & Mid-Tier Markets with Portfolio including Specialty and Niche Products Special Focus Niche & Specialty patented products in the US with early launch 619 opportunity in Emerging Markets 40+ 123 South East Asia Countries Commonwealth of Sugammadex Ferric Marketed Independe
Slide 22: Professional and Experienced Management Team (1/2)
6 Professional and Experienced Management Team (1/2) Sanjay Shaileshbhai Majmudar Swapnil Jatinbhai Shah Deval Rajnikant Shah Chairman & Non-Executive, Promoter & Managing Director Whole-Time Director & CFO Non- Independent Director ▪ Nearly 2 decades of experience in the pharma sector ▪ 40+ years o
Slide 23: Professional and Experienced Management Team (2/2)
6 Professional and Experienced Management Team (2/2) Jignesh Desai Gautam Shah Jatin Gajjar President - Finance President - US Operations Chief Technology Officer ▪ 30+ years of experience in finance and accounting ▪ 30+ years of experience in pharmaceutical ▪ 30+ years of experience in pharmaceutic
Slide 24: Strong R&D Capabilities Driving Differentiated Product Portfolio
Strong R&D Capabilities Driving Differentiated Product Portfolio R&D Site 1 - USA R&D Site 1 - USA Oral Oral Internal research ORS Injectables API In-House R&D in US for Solids Liquids Information available Controlled Substances on subscribed databases Team R&D Site 2 - India 107 people & 3 members
Slide 25: Accredited FDF Manufacturing Facilities (1/2)
5 Accredited FDF Manufacturing Facilities (1/2) Atlanta Facility Ahmedabad, Chhatral Facility 378,943 Sq. Ft. Total Area Facility 12 3 Manufacturing Lines Manufacturing Lines 185,300 Sq. Ft. 4 Total Area Dosage Forms General Oral Beta Lactum Strong Regulatory Track Record Dosage Injectables Orals US
Slide 26: Accredited FDF Manufacturing Facilities (2/2)
Accredited FDF Manufacturing Facilities (2/2) Apnar Pharma Plant ✓ Manufacturing facility commenced in 2021 & USFDA Approval received in September 2022 ✓ 2 land parcel available of total land area of ~49,250 Sq. Mts. ✓ Facility constructed on 1 plot (~4,500 Sq. Mts) with construction of ~40,000 Sq.
Slide 27: Accredited API Manufacturing Facilities
Accredited API Manufacturing Facilities Senores API Plant I & II ✓ The two plants have a land parcel of 15,134 sq. ft. and 230,000 sq. ft. respectively. ✓ Employee Strength – 110+ Employees ✓ The facility integrates manufacturing with an advanced Quality Control Lab dedicated to testing and releasin
Slide 28: Great Place to Work with Active Member of Globally recognized Pharma Associations
3 Great Place to Work with Active Member of Globally recognized Pharma Associations Active Member of Various Globally Recognized Great Place To Work Certified Pharmaceutical Associations & Working Bodies 28
Slide 29: Senores Pharmaceuticals Limited – Contact Us
SENORES PHARMACEUTICALS LIMITED CONTACT US Senores Pharmaceuticals Limited Strategic Growth Advisors Private Limited CIN: L24290GJ2017PLC100263 CIN: U74140MH2010PTC204285 Mr. Deval Shah – Whole Time Director & CFO Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98